Maintenance therapy for ovarian cancer: Of Helsinki and Hippocrates

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4633-4634

  McGuire, William Patrick ^a  

^a Harry and Jeanette Weinberg Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHROMIUM PHOSPHATE P 32; EPIRUBICIN; OREGOVOMAB; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

CANCER RADIOTHERAPY; EDITORIAL; HUMAN; MAINTENANCE THERAPY; MOTOR NEUROPATHY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; TREATMENT OUTCOME; EPITHELIUM CELL; FEMALE; NOTE; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; EPITHELIAL CELLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70350444788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6653     Document Type: Editorial

References (8)

1. Pecorelli S, Favalii G, Gaducci A, et al: Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 Protocol 1. J Clin Oncol 27:4642-4648, 2009
2. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
3. National Institutes of Health: Office of Human Subjects Research. Regulations and ethical guidelines: World Medical Association Declaration of Helsinki. http://ohsr.od.nih.gov/guidelines/helsinki.html
4. Cannistra SA: The ethics of early stopping rules: Who is protecting whom? J Clin Oncol 22:1542-1545, 2004
5. Markman M, Liu PY, Rothenberg ML, et al: Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454-1458, 2006
6. Liu PY, Alberts DS, Monk BJ, et al: An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615-3620, 2007
7. Markman M: Maintenance chemotherapy in advanced ovarian cancer: The US experience. Int J Gynecol Cancer 18:40-43, 2008 (suppl 1)
8. Markman M: Ethical conflict in providing informed consent for clinical trials: A problematic example from the gynecologic cancer research community. Oncologist 9:3-7, 2004